Chronic obstructive pulmonary disease (COPD) is a common condition with an estimated prevalence of 12% in adults over the age of 30 years worldwide. COPD is a leading cause of morbidity and mortality globally, with a substantial economic and social burden. There are an estimated 3 million deaths annually due to COPD. However, most of the patients with COPD respond to routine interventions like bronchodilator therapy, assessing supplemental oxygen needs, smoking cessation, vaccinations, and pulmonary rehabilitation. There is a significant number of patients who unfortunately progress to have persistent symptoms despite these interventions. Refractory COPD is not yet formally defined. Patients with severe persistent symptoms or exacerbations despite appropriate care can be considered to have refractory COPD. Managing refractory COPD needs a multidimensional approach. In this review article, we will discuss essential interventions like ensuring adequate inhaler techniques, exploring the need for non-invasive ventilatory support, use of chronic antibiotics and phosphodiesterase inhibitors to advanced therapies like bronchoscopic lung volume reduction surgery, and the upcoming role of anti-IL5 agents in managing patients with refractory COPD. We will also discuss non-pharmacologic interventions like psycho-social support and nutritional support. We will conclude by discussing the palliative care aspect of managing patients with refractory COPD. Through this review article, we aim to better the approach to managing patients with refractory COPD and discuss new upcoming therapies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11122447 | PMC |
http://dx.doi.org/10.3390/life14050542 | DOI Listing |
Cancers (Basel)
December 2024
Clinical Department of Hematology, Cell Therapies and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Background/objectives: Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections that can affect their clinical outcomes.
Aims: The aims of this study were to assess the following: (1) the incidence of pneumonia in CLL patients treated with venetoclax-based regimens in a real-world setting, (2) the risk factors for event-free survival (EFS), and (3) overall survival (OS).
Methods: This multicenter study included 322 patients from eight centers.
Palliat Med
December 2024
University of Cologne, Faculty of Medicine and University Hospital, Department of Palliative Medicine, Cologne, Germany.
Background: Severe and refractory chronic breathlessness is a common and burdensome symptom in patients with advanced life-limiting disease. Its clinical management is challenging because of the lack of effective interventions.
Aim: To provide practice recommendations on the safe use of pharmacological therapies for severe chronic breathlessness.
J Orthop Surg Res
September 2024
Department of Spine Surgery, Affiliated Hospital of Jining Medical University, Gu Huai Road 89, Jining, 27200, Shandong, P.R. China.
Background: Postoperative refracture of osteoporotic compression fractures in the elderly due to underlying illnesses is a complicated matter involving several variables. A multidisciplinary approach involving orthopedics, geriatrics, endocrinology, and rehabilitation medicine is necessary for an investigation of these issues. investigating the impact of older patients' underlying medical conditions on the refracture of osteoporotic compression fractures following surgery.
View Article and Find Full Text PDFDermatologie (Heidelb)
October 2024
Uniklinik RWTH Aachen, Klinik für Dermatologie und Allergologie, Morillenhang 27, 52074, Aachen, Deutschland.
Background: Chronic inflammatory skin diseases are of great social and medical importance and require effective drug therapy. Phosphodiesterase 4 (PDE4) inhibitors represent a possible therapeutic option by regulating inflammatory processes. PDEs cause the release of proinflammatory cytokines by interfering with signaling pathways.
View Article and Find Full Text PDFDtsch Arztebl Int
September 2024
Department of Otorhinolaryngology - Head and Neck Surgery, Medical Center - University of Freiburg, Freiburg, Germany; Ludwig-Maximilians-University Hospital (LMU) Munich, Medical Clinic V - Pneumology, Munich, Germany; Department of Otorhinolaryngology, Heidelberg University Hospital, Heidelberg, Germany; Division of Sinus and Skull Base Surgery, Traumatology, Department of Otorhinolaryngology, Hospital Karlsruhe, Karlsruhe, Germany; Sinus Academy, Karlsruhe, Germany.
Background: Chronic rhinosinusitis (CRS) is a heterogeneous condition characterized by local chronic inflammation of the mucous membranes of the nose and paranasal sinuses. It affects approximately 5% of the population.
Methods: This review is based on relevant publications retrieved by a selective search of the literature, with particular attention to current national and international guidelines.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!